tickrz reports
  
tickrz rank
D
Endo International PLC (ENDP)
Healthcare | Drug Manufacturers - Other
CEO: Rajiv De Silva
Employees: 6406
endo.com
FACTOR RANKINGSFACTOR SCREENER 
Pure Value RankNOT AVAILABLEDividend RankNO DIVIDEND
Moat Rank457Financial Strength Rank502
Growth Rank387Momentum Rank485
DIVIDEND ANALYSIS
Dividend Yield0%
Payout RatioN/A
3 yr Dividend GrowthN/A
VALUATION RATIOS
P/E Ratiox
P/B Ratio1.21x
P/S Ratio0.65x
EV/EBITDA Ratiox
FINANCIAL STRENGTH
Piotroski F-Score3
Debt-to-Equity377%
Interest Coverage-7.69x
MOAT
ROE-83.5%
ROIC-25.17%
Net Margin-80.39%
GROWTH
5 yr EPS Growth-257.52%
5 yr SPS Growth7.99%
5 yr BPS Growth-6.42%
tickrz Report
 tickrz summary
Unfortunately we don't have enough data to calculate Endo International PLC's tickrz rank.
 value
 pure value ranking Warren Buffett ranking
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Endo International PLC's valuation score is comprised of a P/B ratio of 1.2x, a P/S ratio of 0.7x, Endo International PLC ranks NOT AVAILABLE out of the S&P 500 constituents on valuation--a relatively not available score.Endo International PLC ranks 492 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a weak score, meaning it ranks poorly on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Endo International PLC is probably not for you.

 quality
 moat financial strength
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is weak. Its position within the Healthcare sector appears to be weak. Either the dynamics of its sector place it in a difficult position or management's executition is to blame for its disappointing performance.Endo International PLC has a Piotroski F Score of 3 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of -7.69x, a debt/equity ratio of 377% and a Moat Rank of 457 translate to a weak Financial Strength score.


 momentum
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors.The company has seen its stock fall by -28.5% over the last 12 months. This performance is weak compared to other stocks in the S&P 500, earning it a rank of 485. Based on its 12 month stock performance, Endo International PLC will not appeal to momentum investors.

 yield
 value + yield
Endo International PLC currently does not pay a dividend so it ranks last among S&P 500 companies using our dividend ranking methodology. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

 growth
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the bottom third of S&P500 companies. Its -257.5% 5 year annualized EPS growth, 8% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of -6.4% speak to its relatively poor ranking.

Endo International PLC (ENDP)
Healthcare | Drug Manufacturers - Other
CEO: Rajiv De Silva
Employees: 6406
endo.com


tickrz rank
D

VALUATION RATIOS
P/E Ratiox
P/B Ratio1.21x
P/S Ratio0.65x
EV/EBITDA Ratiox
DIVIDEND ANALYSIS
Dividend Yield0%
Payout RatioN/A
3 yr Dividend GrowthN/A
FINANCIAL STRENGTH
Piotroski F-Score3
Debt-to-Equity377%
Interest Coverage-7.69x
MOAT
ROE-83.5%
ROIC-25.17%
Net Margin-80.39%
GROWTH
5 yr EPS Growth-257.52%
5 yr SPS Growth7.99%
5 yr BPS Growth-6.42%

TICKRZ RANK
Unfortunately we don't have enough data to calculate Endo International PLC's tickrz rank.

PURE VALUE
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Endo International PLC's valuation score is comprised of a P/B ratio of 1.2x, a P/S ratio of 0.7x, Endo International PLC ranks NOT AVAILABLE out of the S&P 500 constituents on valuation--a relatively not available score.

WARREN BUFFETT RANKING
Endo International PLC ranks 492 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a weak score, meaning it ranks poorly on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Endo International PLC is probably not for you.

MOAT
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is weak. Its position within the Healthcare sector appears to be weak. Either the dynamics of its sector place it in a difficult position or management's executition is to blame for its disappointing performance.

FINANCIAL STRENGTH
Endo International PLC has a Piotroski F Score of 3 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of -7.69x, a debt/equity ratio of 377% and a Moat Rank of 457 translate to a weak Financial Strength score.

MOMENTUM
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors.The company has seen its stock fall by -28.5% over the last 12 months. This performance is weak compared to other stocks in the S&P 500, earning it a rank of 485. Based on its 12 month stock performance, Endo International PLC will not appeal to momentum investors.

VALUE + YIELD
Endo International PLC currently does not pay a dividend so it ranks last among S&P 500 companies using our dividend ranking methodology. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

GROWTH
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the bottom third of S&P500 companies. Its -257.5% 5 year annualized EPS growth, 8% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of -6.4% speak to its relatively poor ranking.